Kidney questions about GLP-1s come in two opposite flavors. Some people arrive worried, having read a headline about kidney injury. Others arrive excited, having read one about a breakthrough trial. Both are reading about real things in the labels and the literature, and both usually leave out the sentence that gives each its shape.
Here are the two shapes up front. The warning every one of these labels carries is about dehydration, the indirect route, not a direct attack on the kidney. And the benefit one label now describes was demonstrated in a specific studied population, adults with type 2 diabetes and chronic kidney disease, not in everyone. Neither cancels the other. This article walks through both, in order, and ends with the practical habit that serves either conversation: a dated record of the rough days.
What every label warns about
The warning appears, identically in structure, in the prescribing information across this class, and it has a title worth reading slowly: Acute Kidney Injury Due to Volume Depletion. The label instructs clinicians to monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
The title is the whole story. Volume depletion is the loss of body fluid, and the route the label describes is indirect: fluid lost through vomiting and diarrhea, and less fluid taken in while feeling unwell. The medicine is not described as attacking kidney tissue. The concern is that when fluid leaves faster than it arrives, the kidneys, which depend on adequate flow to do their work, can be caught short. That distinction is the spine of this entire subject, and it explains why the warning lives where it does, attached to the gastrointestinal effects these medicines are known for.
This is also why the subject connects to the digestive side of treatment. Vomiting and diarrhea have their own guide in Diarrhea on a GLP-1: Patterns Worth Tracking; what matters here is not the symptom itself but what a bad stretch of it can do to fluid balance.
Sick days are when it matters
Follow the route and the timing becomes obvious. The situation that matters is not an ordinary Tuesday on a stable dose. It is the sick spell: a day, or worse a run of days, of vomiting or diarrhea, when fluid leaves faster than it arrives and appetite for water disappears along with everything else.
Those are days to call rather than tough out. Not because every stomach bug is a kidney emergency, but because the label's own instruction to clinicians, monitor renal function in patients reporting adverse reactions that could lead to volume depletion, only means something if the care team knows the fluid loss is happening. A call turns a silent risk into a monitored one.
Two things this article will not say, deliberately. It will not set fluid targets, in glasses or liters or any other unit, because none belong in an article; and it will not advise pausing, skipping or delaying a dose during illness, because that decision belongs to the prescriber alone. What to do with the medicine when you cannot keep anything down is exactly the question to ask on the phone call, and the prescriber's answer is the one to follow.
What the postmarketing reports do and do not establish
The postmarketing sections of these labels report acute kidney injury, in some cases requiring hemodialysis. That sentence deserves the same careful reading the warning did, because the section it comes from carries an explicit caveat, the same one that governs every postmarketing list.
The reports come voluntarily from a population of uncertain size. Two things follow. The frequency of these events cannot be reliably estimated: with voluntary reporting, nobody knows the denominator. And a causal relationship cannot be established: a report says a medicine and an event coexisted in someone's chart, not that one caused the other. Neither statement dismisses the reports; they are real and some were serious. Together they mean the reports identify something to watch, not something to conclude from.
So the honest summary of the cautionary direction is: the labels warn about an indirect, dehydration-driven route to kidney injury, and the postmarketing record contains serious reports whose frequency and causation cannot be established. That is a warning to respect on sick days, not a reason to fear the medicine on well ones.
GLP 1 Tracker AppA dated, severity-rated record of rough days, ready for the moment a clinician asks how bad it got.
Get the app
The other direction: FLOW and the kidney indication
Now the opposite flavor of headline, which also rests on something real. Ozempic is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That is the label's own wording, and every clause of it is doing work: the outcome is defined, and the population is named.
The indication came from the FLOW trial, published in 2024. It enrolled 3,533 adults with type 2 diabetes and chronic kidney disease, and it found a 24 percent relative reduction in its main combination of kidney outcomes and cardiovascular death. The FDA approved the indication in January 2025.
Hold onto the population clause especially, because it is what keeps this sentence honest. A 24 percent relative reduction is a group result, measured across thousands of people over the length of a trial. It is not a prediction for any individual, and the studied population was specific: adults with type 2 diabetes and chronic kidney disease. Whether someone outside that population, or anyone in particular inside it, stands to gain from this medicine for kidney reasons is a question for their clinician, who can see their kidney numbers and everything else.
Holding both facts together
The two directions coexist in the same labels without contradiction, and seeing how is the point of the whole subject. One is a dehydration risk that applies to anyone during a bad sick spell, a warning to keep fluid loss from going unmonitored. The other is a benefit demonstrated in a specific population with a specific disease, and approved as an indication for exactly that use. Neither cancels the other, and the second is not a promise to anyone the indication does not name.
Anyone who reads only one half of this ends up with a distorted picture: alarm without the population-scoped benefit, or enthusiasm without the sick-day warning. The kidney story on these medicines is genuinely two stories, and both are worth knowing as they are written, not as headlines compress them. For lab values generally, including why kidney numbers appear on results at all, see Blood Work on a GLP-1: Numbers Worth Keeping.
A dated record of a rough few days
The practical habit serves whichever conversation comes. Log side effects with a severity, on a timeline next to the doses, and a rough few days becomes a dated record: when it started, how bad it got, how long it lasted. That is exactly what a clinician asks for after the fact, and exactly what memory fails to supply, because a miserable week blurs into a vague recollection of being unwell sometime last month.
The log also keeps the sick-day call honest. Being able to say two days of vomiting, one day of keeping nothing down, here are the dates is a different call than I think I had a bug recently. Same medicine, same symptoms, far better information.
That is where this article lands. The warning is real and it is about dehydration; the benefit is real and it is about a named population; the sick days are for calling, not enduring; and the record of all of it takes a minute a day. The rest, including every decision about fluids, doses and tests, belongs to your care team, with your dated log in front of them.
Frequently asked questions
Can GLP-1 medications cause kidney damage?
The warning in every one of these labels is titled Acute Kidney Injury Due to Volume Depletion, and the route it describes is indirect: fluid lost through vomiting and diarrhea, and less fluid taken in, not a direct attack on the kidney. The labels instruct clinicians to monitor renal function in patients reporting adverse reactions that could lead to volume depletion. The postmarketing sections do report acute kidney injury, in some cases requiring hemodialysis, but those reports cannot establish causation or frequency.
Do GLP-1 medications protect the kidneys?
For one studied population, the label now says so. Ozempic is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That indication came from the FLOW trial, which enrolled 3,533 adults and found a 24 percent relative reduction in its main combination of kidney outcomes and cardiovascular death. A group result in that specific population is not a promise to anyone else, and this article will not stretch it.
What did the FLOW trial find about Ozempic and kidneys?
FLOW was published in 2024 and enrolled 3,533 adults with type 2 diabetes and chronic kidney disease. It found a 24 percent relative reduction in its main combination of kidney outcomes and cardiovascular death, and the FDA approved the corresponding kidney indication for Ozempic in January 2025. Two cautions travel with that sentence: it is a group result, and it belongs to the population studied. Whether any individual stands to benefit is a question for their clinician, who can see their kidney numbers.
What do the labels say about monitoring kidneys during vomiting or diarrhea?
The labels instruct clinicians to monitor renal function in patients reporting adverse reactions that could lead to volume depletion, which is the fluid-loss situation that vomiting and diarrhea create. Practically, that makes the days when fluid leaves faster than it arrives the days to call your care team rather than tough it out. The article does not interpret any kidney number; a result on a printout belongs to the clinician who ordered it.
How bad does a sick day have to be before I call about my kidneys?
This article sets no threshold and gives no fluid targets, because the honest answer is that judgment belongs to your clinician. What the labels describe is the situation: fluid lost through vomiting and diarrhea, and less taken in, is when kidney numbers have a reason to move. If you cannot keep fluids down, or symptoms go on for days, that is a call, not a wait. What to do about your dose during illness is part of that call, and the decision belongs to the prescriber alone.